Comprehensive liquid biopsy analysis as a tool for the early detection of minimal residual disease in breast cancer.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
23 01 2023
23 01 2023
Historique:
received:
22
06
2022
accepted:
28
11
2022
entrez:
23
1
2023
pubmed:
24
1
2023
medline:
26
1
2023
Statut:
epublish
Résumé
Liquid biopsy (LB) provides a unique minimally invasive tool to follow-up cancer patients over time, to detect minimal residual disease (MRD), to study metastasis-biology and mechanisms of therapy-resistance. Molecular characterization of CTCs offers additionally the potential to understand resistance to therapy and implement individualized targeted treatments which can be modified during the disease evolution and follow-up period of a patient. In this study, we present a long-term follow-up of operable breast cancer patients based on a comprehensive liquid biopsy analysis. We performed a comprehensive liquid biopsy analysis in peripheral blood of 13 patients with early-stage operable breast cancer at several time points for a period of ten years, consisting of: (a) CTC enumeration using the CellSearch system, (b) phenotypic analysis of CTCs using Immunofluorescence, (c) gene expression analysis, in EpCAM
Identifiants
pubmed: 36690653
doi: 10.1038/s41598-022-25400-1
pii: 10.1038/s41598-022-25400-1
pmc: PMC9870904
doi:
Substances chimiques
Epithelial Cell Adhesion Molecule
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1258Informations de copyright
© 2023. The Author(s).
Références
Pan, H. et al. 20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N. Engl. J. Med. 377, 1836–1846. https://doi.org/10.1056/NEJMoa1701830 (2017).
doi: 10.1056/NEJMoa1701830
Pantel, K. & Alix-Panabières, C. Liquid biopsy and minimal residual disease—Latest advances and implications for cure. Nat. Rev. Clin. Oncol. 16, 409–424. https://doi.org/10.1038/s41571-019-0187-3 (2019).
doi: 10.1038/s41571-019-0187-3
Lianidou, E. & Hoon, D. Circulating tumor cells and circulating tumor DNA, in Tietz Textbook of Clinical Chemistry and Molecular Diagnostics 1111–1144 (2017).
Ma, N. & Jeffrey, S. S. Deciphering cancer clues from blood. Science 1979(367), 1424–1425. https://doi.org/10.1126/science.abb0736 (2020).
doi: 10.1126/science.abb0736
Alix-Panabières, C. The future of liquid biopsy. Nature 579, S9. https://doi.org/10.1038/d41586-020-00844-5 (2020).
doi: 10.1038/d41586-020-00844-5
Lianidou, E. & Pantel, K. Liquid biopsies. Genes Chromosom. Cancer 58, 219–232. https://doi.org/10.1002/gcc.22695 (2019).
doi: 10.1002/gcc.22695
Cortés-Hernández, L. E., Eslami, Z. S., Pantel, K. & Alix-Panabières, C. Molecular and functional characterization of circulating tumor cells: From discovery to clinical application. Clin. Chem. 66, 97–104. https://doi.org/10.1373/clinchem.2019.303586 (2020).
doi: 10.1373/clinchem.2019.303586
Rack, B. et al. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J. Natl. Cancer Inst. 106(5), dju066. https://doi.org/10.1093/jnci/dju066 (2014).
doi: 10.1093/jnci/dju066
Janni, W. J. et al. Pooled analysis of the prognostic relevance of circulating tumor cells in primary breast cancer. Clin. Cancer Res. 22, 2583–2593. https://doi.org/10.1158/1078-0432.CCR-15-1603 (2016).
doi: 10.1158/1078-0432.CCR-15-1603
Bidard, F. C. et al. Efficacy of circulating tumor cell count-driven vs clinician-driven first-line therapy choice in hormone receptor-positive, ERBB2-negative metastatic breast cancer: The STIC CTC randomized clinical trial. JAMA Oncol 7, 34–41. https://doi.org/10.1001/jamaoncol.2020.5660 (2021).
doi: 10.1001/jamaoncol.2020.5660
Müller, V. et al. Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program. ESMO Open https://doi.org/10.1016/j.esmoop.2021.100299 (2021).
doi: 10.1016/j.esmoop.2021.100299
Alix-Panabières, C. & Pantel, K. Liquid biopsy: From discovery to clinical application. Cancer Discov. 11, 858–873. https://doi.org/10.1158/2159-8290.CD-20-1311 (2021).
doi: 10.1158/2159-8290.CD-20-1311
Stathopoulou, A. et al. Real-time quantification of CK-19 mRNA-positive cells in peripheral blood of breast cancer patients using the LightCycler system. Clin. Cancer Res. 9, 5145–5151 (2003).
Stathopoulou, A. et al. A highly specific real-time RT-PCR method for the quantitative determination of CK-19 mRNA positive cells in peripheral blood of patients with operable breast cancer. Int. J. Cancer 119, 1654–1659. https://doi.org/10.1002/ijc.22017 (2006).
doi: 10.1002/ijc.22017
Strati, A. et al. Gene expression profile of circulating tumor cells in breast cancer by RT-qPCR. BMC Cancer https://doi.org/10.1186/1471-2407-11-422 (2011).
doi: 10.1186/1471-2407-11-422
Xenidis, N. et al. Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J. Clin. Oncol. 27, 2177–2184. https://doi.org/10.1200/JCO.2008.18.0497 (2009).
doi: 10.1200/JCO.2008.18.0497
Xenidis, N. et al. Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer. Br. J. Cancer 108, 549–556. https://doi.org/10.1038/bjc.2012.597 (2013).
doi: 10.1038/bjc.2012.597
Xenidis, N. et al. Clinical relevance of circulating CK-19 mRNA-positive cells detected during the adjuvant tamoxifen treatment in patients with early breast cancer. Ann. Oncol. 18, 1623–1631. https://doi.org/10.1093/annonc/mdm208 (2007).
doi: 10.1093/annonc/mdm208
Xenidis, N. et al. Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. J. Clin. Oncol. 24, 3756–3762. https://doi.org/10.1200/JCO.2005.04.5948 (2006).
doi: 10.1200/JCO.2005.04.5948
Xenidis, N. et al. Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer. Ann. Oncol. 14, 849–855. https://doi.org/10.1093/annonc/mdg259 (2003).
doi: 10.1093/annonc/mdg259
Alix-Panabières, C., Mader, S. & Pantel, K. Epithelial-mesenchymal plasticity in circulating tumor cells. J. Mol. Med. (Berl.) 95(2), 133–142. https://doi.org/10.1007/s00109-016-1500-6 (2017).
doi: 10.1007/s00109-016-1500-6
Li, W. et al. Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis. Sci. Rep. https://doi.org/10.1038/s41598-017-14364-2 (2017).
doi: 10.1038/s41598-017-14364-2
Aktas, B. et al. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res https://doi.org/10.1186/bcr2333 (2009).
doi: 10.1186/bcr2333
Kasimir-Bauer, S., Hoffmann, O., Wallwiener, D., Kimmig, R. & Fehm, T. Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells. Breast Cancer Res. https://doi.org/10.1186/bcr3099 (2012).
doi: 10.1186/bcr3099
Giordano, A. et al. Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. Mol. Cancer Ther. 11, 2526–2534. https://doi.org/10.1158/1535-7163.MCT-12-0460 (2012).
doi: 10.1158/1535-7163.MCT-12-0460
Papadaki, M. A. et al. Circulating tumor cells with stemness and epithelial-to-mesenchymal transition features are chemoresistant and predictive of poor outcome in metastatic breast cancer. Mol. Cancer Ther. 18, 437–447. https://doi.org/10.1158/1535-7163.MCT-18-0584 (2019).
doi: 10.1158/1535-7163.MCT-18-0584
Pore, M. et al. Cancer stem cells, epithelial to mesenchymal markers, and circulating tumor cells in small cell lung cancer. Clin. Lung Cancer 17, 535–542. https://doi.org/10.1016/j.cllc.2016.05.015 (2016).
doi: 10.1016/j.cllc.2016.05.015
Markou, A. et al. Multiplex gene expression profiling of in vivo isolated circulating tumor cells in high-risk prostate cancer patients. Clin. Chem. 64, 297–306. https://doi.org/10.1373/clinchem.2017.275503 (2018).
doi: 10.1373/clinchem.2017.275503
André, F. et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N. Engl. J. Med. 380, 1929–1940. https://doi.org/10.1056/NEJMoa1813904 (2019).
doi: 10.1056/NEJMoa1813904
Markou, A. et al. PIK3CA mutational status in circulating tumor cells can change during disease recurrence or progression in patients with breast cancer. Clin. Cancer Res. 20, 5823–5834. https://doi.org/10.1158/1078-0432.CCR-14-0149 (2014).
doi: 10.1158/1078-0432.CCR-14-0149
Tzanikou, E. et al. PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: A direct comparison study. Mol. Oncol. 13(12), 2515–2530. https://doi.org/10.1002/1878-0261.12540 (2019).
doi: 10.1002/1878-0261.12540
Markou, A., Tzanikou, E., Ladas, I., Makrigiorgos, G. M. & Lianidou, E. Nuclease-assisted minor allele enrichment using overlapping probes-assisted amplification-refractory mutation system: An approach for the improvement of amplification-refractory mutation system-polymerase chain reaction specificity in liquid biopsies. Anal. Chem. 91, 13105–13111. https://doi.org/10.1021/acs.analchem.9b03325 (2019).
doi: 10.1021/acs.analchem.9b03325
Stergiopoulou, D. et al. ESR1 NAPA assay: Development and analytical validation of a highly sensitive and specific blood-based assay for the detection of ESR1 mutations in liquid biopsies. Cancers (Basel) 13, 1–18. https://doi.org/10.3390/cancers13030556 (2021).
doi: 10.3390/cancers13030556
Lampignano, R. et al. A novel workflow to enrich and isolate patient-matched EpCAM
doi: 10.3390/ijms18091885
Deng, G. et al. Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow. BMC Cancer https://doi.org/10.1186/1471-2407-14-456 (2014).
doi: 10.1186/1471-2407-14-456
Pestrin, M. et al. Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients. Mol. Oncol. 9, 749–757. https://doi.org/10.1016/j.molonc.2014.12.001 (2015).
doi: 10.1016/j.molonc.2014.12.001
Carausu, M. et al. ESR1 mutations: A new biomarker in breast cancer. Expert Rev. Mol. Diagn. 19, 599–611. https://doi.org/10.1080/14737159.2019.1631799 (2019).
doi: 10.1080/14737159.2019.1631799
Paolillo, C. et al. Detection of activating estrogen receptor gene (ESR1) mutations in single circulating tumor cells. Clin. Cancer Res. 23, 6086–6093. https://doi.org/10.1158/1078-0432.CCR-17-1173 (2017).
doi: 10.1158/1078-0432.CCR-17-1173
Franken, A. et al. Detection of ESR1 mutations in single circulating tumor cells on estrogen deprivation therapy but not in primary tumors from metastatic luminal breast cancer patients. J. Mol. Diagn. 22, 111–121. https://doi.org/10.1016/j.jmoldx.2019.09.004 (2020).
doi: 10.1016/j.jmoldx.2019.09.004
Hanahan, D. Hallmarks of cancer: New dimensions. Cancer Discov. 12, 31–46. https://doi.org/10.1158/2159-8290.CD-21-1059 (2022).
doi: 10.1158/2159-8290.CD-21-1059
Mastoraki, S. et al. ESR1 methylation: A liquid biopsy-based epigenetic assay for the follow-up of patients with metastatic breast cancer receiving endocrine treatment. Clin. Cancer Res. 24, 1500–1510. https://doi.org/10.1158/1078-0432.CCR-17-1181 (2018).
doi: 10.1158/1078-0432.CCR-17-1181
Georgoulias, V. et al. Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: Results of a randomized phase II study. Ann. Oncol. 23, 1744–1750. https://doi.org/10.1093/annonc/mds020 (2012).
doi: 10.1093/annonc/mds020
Mavroudis, D. et al. Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: A multicenter randomized study by the Hellenic Oncology Research Group (HORG). Ann. Oncol. 26, 1333–1340. https://doi.org/10.1093/annonc/mdv213 (2015).
doi: 10.1093/annonc/mdv213
Stathopoulou, A. et al. Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: Evaluation of their prognostic significance. J. Clin. Oncol. 20, 3404–3412. https://doi.org/10.1200/JCO.2002.08.135 (2002).
doi: 10.1200/JCO.2002.08.135
Ignatiadis, M. et al. Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer. Clin. Cancer Res. 14, 2593–2600. https://doi.org/10.1158/1078-0432.CCR-07-4758 (2008).
doi: 10.1158/1078-0432.CCR-07-4758
Saloustros, E. et al. Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: Prognostic relevance for late relapse. Breast Cancer Res. 13, R60. https://doi.org/10.1186/bcr2897 (2011).
doi: 10.1186/bcr2897
Georgoulias, V. et al. Effect of front-line chemotherapy on circulating CK-19 mRNA-positive cells in patients with metastatic breast cancer. Cancer Chemother. Pharmacol. 74, 1217–1225. https://doi.org/10.1007/s00280-014-2598-2 (2014).
doi: 10.1007/s00280-014-2598-2
Matikas, A. et al. Detection of circulating tumour cells before and following adjuvant chemotherapy and long-term prognosis of early breast cancer. Br. J. Cancer 126(11), 1563–1569. https://doi.org/10.1038/S41416-022-01699-5 (2022).
doi: 10.1038/S41416-022-01699-5
Najim, O. et al. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1). Cancer Treat. Res. Commun. https://doi.org/10.1016/j.ctarc.2019.100123 (2019).
doi: 10.1016/j.ctarc.2019.100123
Schiavon, G. et al. Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Sci. Transl. Med. https://doi.org/10.1126/scitranslmed.aac7551 (2015).
doi: 10.1126/scitranslmed.aac7551
Jeselsohn, R. et al. Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin. Cancer Res. 20, 1757–1767. https://doi.org/10.1158/1078-0432.CCR-13-2332 (2014).
doi: 10.1158/1078-0432.CCR-13-2332
Toy, W. et al. Activating ESR1 mutations differentially affect the efficacy of ER antagonists. Cancer Discov. 7, 277–287. https://doi.org/10.1158/2159-8290.CD-15-1523 (2017).
doi: 10.1158/2159-8290.CD-15-1523
Chandarlapaty, S. et al. Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: A secondary analysis of the BOLERO-2 clinical trial. JAMA Oncol. 2, 1310–1315. https://doi.org/10.1001/jamaoncol.2016.1279 (2016).
doi: 10.1001/jamaoncol.2016.1279
Paoletti, C. et al. Comprehensive mutation and copy number profiling in archived circulating breast cancer tumor cells documents heterogeneous resistance mechanisms. Can. Res. 78, 1110–1122. https://doi.org/10.1158/0008-5472.CAN-17-2686 (2018).
doi: 10.1158/0008-5472.CAN-17-2686
Bidard, F. C. et al. Prognostic impact of ESR1 mutations in ER+ HER2− MBC patients prior treated with first line AI and palbociclib: An exploratory analysis of the PADA-1 trial. 38, 1010–1010. https://doi.org/10.1200/JCO.2020.38.15_suppl.1010 (2020).
Bidard, F. C. et al. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): A randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. https://doi.org/10.1016/S1470-2045(22)00555-1 (2022).
doi: 10.1016/S1470-2045(22)00555-1
Bozionellou, V. et al. Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer. Clin. Cancer Res. 10, 8185–8194. https://doi.org/10.1158/1078-0432.CCR-03-0094 (2004).
doi: 10.1158/1078-0432.CCR-03-0094
Bredemeier, M. et al. Gene expression signatures in circulating tumor cells correlate with response to therapy in metastatic breast cancer. Clin. Chem. 63, 1585–1593. https://doi.org/10.1373/clinchem.2016.269605 (2017).
doi: 10.1373/clinchem.2016.269605
Vasseur, A., Kiavue, N., Bidard, F. C., Pierga, J. Y. & Cabel, L. Clinical utility of circulating tumor cells: An update. Mol. Oncol. 15, 1647–1666. https://doi.org/10.1002/1878-0261.12869 (2021).
doi: 10.1002/1878-0261.12869
Strati, A. et al. Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma. Ann. Oncol. 28, 1923–1933 (2017).
doi: 10.1093/annonc/mdx206
Zavridou, M. et al. Evaluation of preanalytical conditions and implementation of quality control steps for reliable gene expression and DNA methylation analyses in liquid biopsies. Clin. Chem. 64, 1522–1533. https://doi.org/10.1373/clinchem.2018.292318 (2018).
doi: 10.1373/clinchem.2018.292318
Strati, A., Nikolaou, M., Georgoulias, V. & Lianidou, E. Prognostic significance of TWIST1, CD24, CD44, and ALDH1 transcript quantification in EpCAM-positive circulating tumor cells from early stage breast cancer patients. Cells 8, 652. https://doi.org/10.3390/cells8070652 (2019).
doi: 10.3390/cells8070652
Chimonidou, M. et al. DNA methylation of tumor suppressor and metastasis suppressor genes in circulating tumor cells. Clin. Chem. 57, 1169–1177. https://doi.org/10.1373/clinchem.2011.165902 (2011).
doi: 10.1373/clinchem.2011.165902
Vorkas, P. A. et al. PIK3CA hotspot mutation scanning by a novel and highly sensitive high-resolution small amplicon melting analysis method. J. Mol. Diagn. 12, 697–704. https://doi.org/10.2353/jmoldx.2010.100008 (2010).
doi: 10.2353/jmoldx.2010.100008
Jeannot, E. et al. A single droplet digital PCR for ESR1 activating mutations detection in plasma. Oncogene https://doi.org/10.1038/s41388-020-1174-y (2020).
doi: 10.1038/s41388-020-1174-y
Chimonidou, M. et al. Direct comparison study of DNA methylation markers in EpCAM-positive circulating tumour cells, corresponding circulating tumour DNA, and paired primary tumours in breast cancer. Oncotarget 8, 72054–72068. https://doi.org/10.18632/oncotarget.18679 (2017).
doi: 10.18632/oncotarget.18679
Kallergi, G. et al. Apoptotic circulating tumor cells in early and metastatic breast cancer patients. Mol. Cancer Ther. 12, 1886–1895. https://doi.org/10.1158/1535-7163.MCT-12-1167 (2013).
doi: 10.1158/1535-7163.MCT-12-1167
Kallergi, G., Mavroudis, D., Georgoulias, V. & Stournaras, C. Phosphorylation of FAK, PI-3K, and impaired actin organization in CK-positive micrometastatic breast cancer cells. Mol. Med. 13, 79–88. https://doi.org/10.2119/2006-00083.Kallergi (2007).
doi: 10.2119/2006-00083.Kallergi
Kallergi, G. et al. Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients. Breast Cancer Res. https://doi.org/10.1186/bcr2149 (2008).
doi: 10.1186/bcr2149
Kallergi, G. et al. Hypoxia-inducible factor-1α and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients. Breast Cancer Res. https://doi.org/10.1186/bcr2452 (2009).
doi: 10.1186/bcr2452
Spiliotaki, M. et al. Evaluation of proliferation and apoptosis markers in circulating tumor cells of women with early breast cancer who are candidates for tumor dormancy. Breast Cancer Res. https://doi.org/10.1186/s13058-014-0485-8 (2014).
doi: 10.1186/s13058-014-0485-8
Kallergi, G. et al. Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients. Breast Cancer Res. https://doi.org/10.1186/s13058-015-0624-x (2015).
doi: 10.1186/s13058-015-0624-x